PharmaLytica 2021 Hyderabad review.

India's demand for Covid-19 drug remdesivir likely to fall: Cipla

India's average daily coronavirus caseload was about 53,000 in October and November, and plunged to around 27,000 in December. Daily cases had hit a peak in September.

17 February 2021 Mumbai; India's demand for Covid-19 drug remdesivir will likely fall in coming months, as daily coronavirus infections in the country continue to decline, said Drugmaker Cipla on Tuesday.

In India, Cipla was among the first companies to launch a generic version of remdesivir, developed by US-based Gilead Sciences, and as of September had sold more than 300,000 vials across India.

Kedar Upadhye, Cipla's global chief financial officer said, "There is a direct link between the number of cases and remdesivir sales," He did not provide details on how much he expected demand to fall.

Upadhye also added, Demand for the drug was still robust in October and November, but began to drop in December.

India's average daily coronavirus caseload was about 53,000 in October and November, and plunged to around 27,000 in December. Daily cases had hit a peak in September.

The World Health Organization in November advised that the drug not be used for patients hospitalized with Covid-19, for lack of evidence it could improve patient survival.

But there has been no change to protocols on remdesivir's use in India, Upadhye said.

Mumbai-headquartered Cipla said on Friday its consolidated net profit more than doubled during the three months ended December 31, helped by higher demand for other drugs across its portfolio.


Kedar Upadhye, Cipla's Global Chief Financial Officer.
×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More